TLR7 and neoplasm: Following TransCon TLR7/8 Agonist administration, significantly elevated proinflammatory cytokine and chemokine expression was detected in the tumor over 7 days, consistent with sustained release of resiquimod from TransCon TLR7/8 Agonist within the TME (Fig. 2C).